Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib and Dacarbazine in Metastatic Melanoma
NCT00597038Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2007
- Primary completion
- Sep 2011
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of dasatinib in melanoma (2 arms), sponsored by Moffitt Cancer Center. Primary endpoints: Recommended Phase II Dose and Overall Response Rate. Started Nov 2007; status: completed.
02
Drugs
dasatinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00597038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00597038.